Visceral Leishmaniasis in a Patient Taking Adalimumab for Rheumatoid Arthritis.
Medical journal of Australia(2013)
摘要
Notable Cases tic infection, malignancy or a m trexate and adalimumab were n Her clinical status deteriorate ening malaise and fevers. Over th developed pancytopenia with 0.7 109/L (RI, 1.8–7.7 109/L), h and platelet count of 32 109/L gammaglobulin concentration 13.9 g/L), and her ferritin level in Opportunistic infections have been increasingly recognised with the advent of biological therapy for rheumatic disease. Visceral leishmaniasis (VL) has been reported in Europe in association with tumour necrosis factor-alpha inhibitors. We report the first case of VL in an Australian returned traveller taking adalimumab.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要